Loading…
← CockpitCompetitor Analysis › SUDEEPPHRM.NS Sudeep Pharma LimitedOpen in the cockpit ↗

Sudeep Pharma LimitedSUDEEPPHRM.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Other

Manufactures pharmaceutical-grade mineral compounds (calcium, magnesium, zinc salts) used as excipients and nutraceutical ingredients.

≈ A niche pharma-grade mineral excipient makerMomentum leader 95
Mkt cap
$1.45B
US dollars, full cap
Free float
21%
of shares outstanding
$/day
$3.08M
20-day average traded
Fwd P/E
69.1×
forward earnings
ROIC−WACC
+2.7 pp
WACC 13.7%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · INR₹1,202
1D-1.3%
1W-0.5%
1M+19.8%
3M+8.9%
6M+85.3%
YTD+99.5%
1Yn/a
ATR %4.8%
Beta0.78
52w lowhigh12.8% off high

What Sudeep Pharma does

Manufactures pharmaceutical-grade mineral compounds (calcium, magnesium, zinc salts) used as excipients and nutraceutical ingredients.

In one line: A niche pharma-grade mineral excipient maker.

Products and services

  • Calcium/magnesium compounds
  • Zinc/other mineral salts
  • Nutraceutical ingredients

Customers

  • Pharma formulation companies
  • Nutraceutical/food companies

Where it sits in the supply chain

  • Mineral salt synthesis
  • Pharma-grade excipient manufacturing
  • Sale to pharma/nutraceutical makers

What could go right

  • Nutraceutical/pharma excipient demand growth

What could go wrong

  • Customer/product concentration
  • Commodity mineral input cost swings

Moat: narrow (process know-how, regulatory licence). Pharma-grade quality certifications for mineral excipients create a technical barrier versus commodity suppliers.

Headquarters: Gujarat, India · Employees: 651

Named competitors

  • Anmol Chemicals private or unlisted
  • SPI Pharma private or unlisted

Sudeep Pharma at a glance

Size Sudeep Pharma (SUDEEPPHRM.NS) is an India Health Care company (Pharmaceuticals: Other) with a market value of $1.45B, the 488th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,202 on 18 Nov 2026.

Performance Over six months the shares gained 85.3%, against -8.1% for the median peer and +3.8% for the India market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 26.8% over the last twelve months (peer median +9.3%); the operating margin is 32.9% (peer median 15.1%).

Valuation It trades at 69.1× forward earnings against a peer median of 16.2× (2nd most expensive of 18).

Capital Return on invested capital runs 2.7 points above its cost of capital (13.7% WACC).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026SUDEEPPHRM.NS 185Peer median 90
Six months, rebased to 100: Sudeep Pharma against the median of its 20 peers (local-currency closes).

Sudeep Pharma financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹7.10B₹6.39B₹4.97B₹4.55B₹4.26B
Revenue growth—+28%+9%+7%—
Gross profit₹3.87B₹3.17B₹2.57B₹2.25B₹1.44B
EBITDA₹2.51B₹2.31B₹1.90B₹1.80B₹886M
Net income₹1.88B₹1.73B₹1.39B₹1.33B₹623M
Free cash flown/a-₹566M-₹208M₹95.9M-₹33.1M
Capital expendituren/a₹1.18B₹642M₹525M₹472M
Total debt₹1.89B₹1.50B₹1.38B₹787M₹831M

Quarterly statements and history in the cockpit →

Sudeep Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%600216002287JWEL3003636472BIOG-BPHMCRON21426000560022750719GRANULESAPN1112PHN0460SUDEEPPHRM.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Sudeep Pharma is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×100×600216JWEL6472BIOG-BPHMCRON2142002275GRANULESAPN11120022196007500460SUDEEPPHRM.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sudeep Pharma is the large dot.

Sudeep Pharma competitors and peer comparison

How Sudeep Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sudeep Pharma against its 20 peers (data as of 18 Nov 2026)
MeasureSUDEEPPHRM.NSPeer medianRank in peer set
1-month return+19.8%-2.3%3rd highest of 21
6-month return+85.3%-8.1%2nd highest of 21
Distance from 52-week high-12.8%-29.7%5th highest of 21
Revenue growth (TTM)+26.8%+9.3%6th highest of 21
Operating margin32.9%15.1%2nd highest of 21
Forward P/E69.1×16.2×2nd most expensive of 18
ROIC minus cost of capital+2.7 pp+4.0 pp11th highest of 21
EV / EBITDA54.5×17.3×most expensive of 12
Net debt / EBITDA0.3×-0.3×4th most indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Sudeep Pharma SUDEEPPHRM.NSIndia$1.45B+85%+27%33%69.1×n/an/a
Zhejiang Medicine 600216.SSChina$1.51B-26%-6%7%11.5×-7.8%+3.9%
Tibet Cheezheng Tibetan Medicine 002287.SZChina$1.58B-17%-7%28%n/a-1.9%+10.4%
Jamieson Wellness JWEL.TOCanada$1.32B+32%+12%13%20.6×13.5%+15.3%
Porton Pharma Solutions 300363.SZChina$1.66B+37%+6%-2%n/a2.1%+10.4%
Bora Pharmaceuticals 6472.TWTaiwan$1.25B-2%+7%14%10.8×3.5%+60.2%
BioGaia BIOG-B.STSweden$1.25B-4%+13%28%31.0×1.5%+15.5%
Pharma Mar PHM.MCSpain$1.21B-38%+32%19%41.4×10.6%-3.9%
Cronos CRON.TOCanada$1.17B+24%+55%5%16.2×18.8%+26.7%
HBM 2142.HKHong Kong$1.12B-18%+55%44%11.7×13.1%+62.3%
China Meheco 600056.SSChina$1.90B-16%+2%3%n/a-1.3%-2.1%
Guilin Sanjin Pharmaceutical 002275.SZChina$1.05B-12%-3%24%12.8×-8.7%+5.5%
Shandong Xinhua Pharmaceutical 0719.HKHong Kong$1.03B-19%-1%4%6.2×-2.1%+7.1%
Granules India GRANULES.NSIndia$2.12B+4%+22%17%24.8×23.6%+10.6%
Applied Nutrition APN.LUnited Kingdom$986M+31%+51%25%21.4×24.6%+38.5%
Health and Happiness (H&H) International 1112.HKHong Kong$2.15B+108%+24%16%13.2×-1.7%+4.4%
New Journey Health Technology Group Co., Ltd.Class A 002219.SZChina$942M-18%-14%8%182.0×n/an/a
China Resources Jiangzhong Pharmaceutical 600750.SSChina$2.27B+4%-10%24%16.5×-1.9%+11.6%
PharmaNutra PHN.MIItaly$922M+2%+17%22%33.5×4.7%+18.5%
China Resources Double-Crane Pharmaceutical 600062.SSChina$2.35B-14%-1%13%9.3×-9.1%+5.3%
Sihuan Pharmaceutical 0460.HKHong Kong$856M-34%+30%15%8.7×n/an/a

Questions

Who are Sudeep Pharma's main competitors?
Named competitors: Anmol Chemicals (private or unlisted), SPI Pharma (private or unlisted). The cockpit's measured peer set (industry) also includes Zhejiang Medicine (600216.SS), Tibet Cheezheng Tibetan Medicine (002287.SZ), Jamieson Wellness (JWEL.TO), Porton Pharma Solutions (300363.SZ), Bora Pharmaceuticals (6472.TW), BioGaia (BIOG-B.ST).
Is Sudeep Pharma expensive compared with its peers?
On forward p/e it trades at 69.1× against a peer median of 16.2×, 2nd most expensive of 18 in its peer set.
How has Sudeep Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned +85.3% against -8.1% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.